GeoVax (GOVX) Reports 2025 Year-End Financial Results and Provides Business Update

LIVE QUOTE Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine) Scheduled to Initiate During the Second Half of This Year ATLANTA, GA - April 15, 2026 (NEWMEDIAWIRE)...

Report: AI Powered Review on GeoVax (GOVX) $1.15

In our view, a research report is designed to gather information on publicly traded companies from press releases, management presentations (including power points), SEC...

Biotech Stock Review is Back! Timing Feels Perfect. 4 Companies Added to Watch List.

Biotech 12 Pack Watch List to be Released. Cabaletta (CABA) $3.07, GeoVax (GOVX) $1.14, PolyPid (PYPD) $4.68, Replimune (REPL) $2.17. In 2020, we Released the "Biotech...

GeoVax (GOVX) Reports Both Favorable Safety and “It’s Working” News for its Cancer...

Official Headline is "GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck...

GeoVax (GOVX) Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen...

https://youtu.be/4LffUyg6yE8?si=G8_kZMce8yHGCxKp GEO-CM04S1 Offers Solution to Overcome HHS-Cited mRNA Deficiencies - Potentially Offering Broader, More Durable Protection ATLANTA, GA - August 7, 2025 (NEWMEDIAWIRE) - GeoVax Labs,...

Nine Page Summary Report on GeoVax (GOVX)

This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier 44-page report, we printed it out and...

GeoVax (GOVX) Provides First Half 2024 Business Update.

Award of BARDA Project NextGen contract represents a significant milestone event; Total value of award to GeoVax and its CRO partner total approximately $367-388 million BARDA-funded...

GeoVax Receives Massive $300+ Million BARDA Project NextGen Award!

Are we happy, you betcha! We just got back from St Croix where the team from the Beverage Stock Review visited the Mutiny Island Vodka...

GeoVax (GOVX) Research Reports Archive

Research Report Archive Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research. Jason Kolbert at Dawson James Securities. Vernon...

GeoVax to Provide Corporate Update on Tuesday May 14, 2024.

Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market cap, addressing...

Latest article

We’re Up 360% in Six Weeks. Replimune (REPL).

That's a Gain of $604 Million, and That Ain't Bad! Six brokerage firms downgraded Replimune (REPL), around the same time we added it to...

GeoVax (GOVX) Conference Call and Transcript.

Excellent Presentation. You Can Listen for 40 Minutes, or Read it in About Ten, Halleluiah. Guess what we'll choose to do? We have no...

Sekur Private Data (SWISF) Awarded Distribution Agreement With Elyon International.

Top Ranked Defense, Government and Enterprise Contractor Trying to Break Over $0.06. We are still sitting on the edge of our seat waiting for contract news,...